Abstract 5802
Background
In Poland, governmental policy was to offer a uniform, national therapeutic programme for the treatment of HER2-positive advanced breast cancer (ABC) patients (pts). Accordingly, the Polish Breast Cancer Treatment Programme was introduced. Herein, we present first results of this effort from the cohort of previously-treated patients who underwent anti-HER2 palliative therapy with lapatinib plus capecitabine.
Methods
The aim of the study was to assess the population-based value of lapatinib plus capecitabine therapy of HER2-positive ABC patients treated within the Polish Breast Cancer Treatment Programme during the years 2008-2015. Patients have been prospectively enrolled into aforementioned programme and treated according to the specified protocol. We used Kaplan-Meier method to evaluate progression-free survival (PFS), time to tumor progression (TTP) and overall survival (OS). The effects of clinical and demographic factors on PFS and OS were assessed using Cox’s proportional hazards regression model.
Results
A total of 1018 HER2-positive ABC women were enrolled into the Polish Breast Cancer Treatment Programme on a national level. Patients who progressed after regimens that included, but were not limited to, anthracyclines, taxanes, and trastuzumab were eligible to this study. Median age of the patients was 56.6 years (range, 22.8 to 86.1). Previous adjuvant therapy: 35.7% pts; ER(+)/PgR(+): 47.5% pts; number of metastatic sites ≥2: 45.9% pts. The median PFS was 6.4 months and median TTP was 6.7 months. The median OS was 11.76 months (range, 0.36-70.32). The overall response rate was 13%. Cox regression model data will be presented.
Conclusions
To our knowledge this study represents one of the first reports assessing the population-based value of a lapatinib/capecitabine treatment in clinical practice. Our data essentially corroborated findings obtained from randomized clinical trials. It seems that treatment with lapatinib and capecitabine is associated with a meaningful clinical effectiveness and therefore warrants consideration in the treatment algorithm of HER2-positive ABC patients.
Clinical trial identification
Legal entity responsible for the study
Beata Jagielska.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract